CAJ | 학술논문

目的：探讨低频重复经颅磁刺激（ rTMS）联合文拉法辛治疗广泛性焦虑障碍的早期临床疗效。方法将40例首发广泛性焦虑障碍患者随机分成两组，研究组采用rTMS联合文拉法辛治疗，对照组单用文拉法辛治疗。分别于治疗前及治疗后第1、2周末应用汉密尔顿焦虑量表（HAMA）及焦虑自评量表（SAS）评定临床疗效，采用治疗中需处理的不良反应症状量表（ TESS）评定不良反应。结果研究组和对照组HAMA总分及各因子分、SAS总分在治疗后第1、2周末较治疗前均下降（P＜0．05）。研究组HAMA总分及各因子分、SAS总分在治疗后第2周末低于对照组（P＜0．05）。研究组显效率在治疗后第2周末高于对照组（P＜0．05）。两组间不良反应发生率比较无显著性差异（P＞0．05）。结论低频重复经颅磁刺激联合文拉法辛治疗广泛性焦虑障碍疗效好，起效快，优于单一用药。
목적：탐토저빈중복경로자자격（ rTMS）연합문랍법신치료엄범성초필장애적조기림상료효。방법장40례수발엄범성초필장애환자수궤분성량조，연구조채용rTMS연합문랍법신치료，대조조단용문랍법신치료。분별우치료전급치료후제1、2주말응용한밀이돈초필량표（HAMA）급초필자평량표（SAS）평정림상료효，채용치료중수처리적불량반응증상량표（ TESS）평정불량반응。결과연구조화대조조HAMA총분급각인자분、SAS총분재치료후제1、2주말교치료전균하강（P＜0．05）。연구조HAMA총분급각인자분、SAS총분재치료후제2주말저우대조조（P＜0．05）。연구조현효솔재치료후제2주말고우대조조（P＜0．05）。량조간불량반응발생솔비교무현저성차이（P＞0．05）。결론저빈중복경로자자격연합문랍법신치료엄범성초필장애료효호，기효쾌，우우단일용약。
Objective To explore the early effectiveness of low frequency repetitive transcranial magnetic stimulation( rTMS) combined with venlafaxine in treatment of patients with generalized anxiety disorder(GAD).Methods A total of 40 patients with GAD were randomly divided into study group treated with rTMS combined with venlafaxine and control group treated with venlafaxine monotherapy.They were assessed with Hamilton Anxiety Scale (HAMA), Self-Rating Anxiety Scale (SAS) and Treatment Emergent Symptom Scale (TESS) at baseline and at the 1st, 2nd weekend of treatment.Results At the 1st and 2nd weekend of treatment, the total scores of HAMD and SAS as well as all factor scores of HAMA in two groups were all significantly lower than those before treatment(P<0.05).At the 2nd weekend of treatment, the total scores of HAMD and SAS as well as all factor scores of HAMA in study group were all significantly lower than those in control group(P<0.05).At the 2nd weekend of treatment, the effective rate in study group was significantly higher than that in control group(P<0.05).There was no difference for incidence of side effects between two groups(P >0.05).Conclusion It’s effective and rapid for rTMS combined with venlafaxine in the treatment of patients with GAD, which is better than venlafaxine monotherapy.